Privia Health Group (PRVA) – Investment Analysts’ Weekly Ratings Updates

Privia Health Group (NASDAQ: PRVA) recently received a number of ratings updates from brokerages and research firms:

• 4/15/2025 – Privia Health Group had its price target raised by analysts at Robert W. Baird from $24.00 to $26.00. They now have an “outperform” rating on the stock.
• 4/10/2025 – Privia Health Group had its price target raised by analysts at Barclays PLC from $21.00 to $23.00. They now have an “equal weight” rating on the stock.
• 4/10/2025 – Privia Health Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
• 4/10/2025 – Privia Health Group had its price target raised by analysts at Truist Financial Co. from $27.00 to $28.00. They now have a “buy” rating on the stock.
• 3/21/2025 – Privia Health Group had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $30.00 price target on the stock.
• 2/28/2025 – Privia Health Group was given a new $29.00 price target on by analysts at JMP Securities.
• 2/28/2025 – Privia Health Group had its price target raised by analysts at Piper Sandler from $25.00 to $40.00. They now have an “overweight” rating on the stock.
• 2/28/2025 – Privia Health Group had its price target raised by analysts at Canaccord Genuity Group Inc. from $29.00 to $30.00. They now have a “buy” rating on the stock.
• 2/28/2025 – Privia Health Group had its price target raised by analysts at Needham & Company LLC from $25.00 to $30.00. They now have a “buy” rating on the stock.

Privia Health Group Price Performance

PRVA opened at $23.60 on Monday. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.04. The business has a 50-day moving average of $23.82 and a two-hundred day moving average of $21.73. The stock has a market capitalization of $2.86 billion, a price-to-earnings ratio of 235.97, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88.

Insider Activity at Privia Health Group

In other news, CFO David Mountcastle sold 5,630 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the sale, the chief financial officer now owns 179,676 shares of the company’s stock, valued at approximately $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.70% of the stock is owned by insiders.

Institutional Investors Weigh In On Privia Health Group

Several institutional investors and hedge funds have recently made changes to their positions in PRVA. First Horizon Advisors Inc. raised its stake in Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company’s stock worth $35,000 after acquiring an additional 632 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company’s stock worth $47,000 after purchasing an additional 2,350 shares during the period. Financial Management Professionals Inc. bought a new stake in shares of Privia Health Group in the 4th quarter worth approximately $51,000. GAMMA Investing LLC lifted its holdings in shares of Privia Health Group by 113.1% in the 1st quarter. GAMMA Investing LLC now owns 2,866 shares of the company’s stock worth $64,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Quadrant Capital Group LLC boosted its position in Privia Health Group by 11.8% during the 4th quarter. Quadrant Capital Group LLC now owns 4,855 shares of the company’s stock valued at $95,000 after purchasing an additional 511 shares during the period. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.